Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead ' s and Merck ' s Combo Therapy

Gilead Sciences Inc GILD and Merck & Co Inc MRK released results from the Phase 2 clinical study evaluating the combination of islatravir and lenacapavir for HIV infection. At 24 weeks, the investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL),…#gileadsciencesinc #merckcoincmrk #biktarvy #n52 #grade1 #healthcare #gsk
Source: Reuters: Health - Category: Consumer Health News Source Type: news